MVZ - Kurfürstendamm

Recent papers from MVZ - Kurfürstendamm

1. Orchestrating leadership communication during hospital incident command activation: A grounded theory studyInternational Journal of Disaster Risk Reduction · 2026
2. Effects of coaching with data management system intervention or usual care on glycemic control in patients with type 2 diabetes: A multicentre, randomised controlled trialDiabetes Obesity and Metabolism · 2026
3. Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal CancerJournal of Clinical Oncology · 2025
4. Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal CancerJournal of Clinical Oncology · 2025
5. First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)European Journal of Cancer · 2025
6. Real-Life Monitoring: Precise Onset of Action after BotulinumtoxinA InjectionJU Open Plus · 2025
7. Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE ‐4.5 studyMolecular Oncology · 2024
8. Evaluating PlanetScope and UAV Multispectral Data for Monitoring Winter Wheat and Sustainable Fertilization Practices in Mediterranean AgroecosystemsRemote Sensing · 2024
9. Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor InjectionSHILAP Revista de lepidopterología · 2024
10. Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade after Approval: A Single-Blind Study to Evaluate the Reduction in Pain in OnabotulinumtoxinA Detrusor Injection Using Different Injection NeedlesToxins · 2024
11. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)ESMO Open · 2024
12. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe studyAnnals of Hematology · 2024
13. Abortion in the First Trimester. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015-094, December 2022) – Part 1 with Recommendations on Care Structures, Information and Advice on Decision-Making, Measures Before Abortion and Medical AbortionGeburtshilfe und Frauenheilkunde · 2023
14. Pb1938: Real World Effectiveness and Safety of Venetoclax in Combination With Obinutuzumab in Treatment Naive CLL Patients – Data From the Observational Study VerveHemaSphere · 2023
15. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) StudyJournal of Clinical Oncology · 2023
16. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in GermanyInternational Journal of Cancer · 2023
17. Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trialHematological Oncology · 2023
18. Artificial intelligence assisted diagnoses of fine-needle aspiration of breast diseases: a single-center experienceJournal of Digital Health · 2023
19. Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients—Preliminary ResultsToxins · 2022
20. Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study VerveBlood · 2022